{"nctId":"NCT00441285","briefTitle":"Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)","startDateStruct":{"date":"2010-01"},"conditions":["Neurocysticercosis","Epilepsy"],"count":156,"armGroups":[{"label":"I. ABZ + ABZ Placebo + PZQ","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Praziquantel","Drug: Albendazole","Drug: ABZ Placebo"]},{"label":"II.- ABZ + ABZ Placebo + PZQ Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Albendazole","Drug: ABZ Placebo","Drug: PZQ Placebo"]},{"label":"III .- Albendazole + PZQ Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Albendazole","Drug: PZQ Placebo"]}],"interventions":[{"name":"Praziquantel","otherNames":["PZQ"]},{"name":"Albendazole","otherNames":["ABZ"]},{"name":"ABZ Placebo","otherNames":["Placebo of Albendazole"]},{"name":"PZQ Placebo","otherNames":["Placebo of PZQ"]}],"eligibilityModule":{"eligibilityCriteria":"For parent study:\n\nInclusion Criteria:\n\n* Male or female individuals between 16 to 65 years of age, with a diagnosis of Neurocysticercosis and 20 or less viable cysts.\n* Patients with a diagnosis of epilepsy secondary to Neurocysticercosis and a history of one or more spontaneous seizures within the previous year but not longer than 10 years.\n* Willingness to complete a minimum of two weeks of hospitalization.\n* If female of child bearing potential, negative urine pregnancy testing and willingness to use an adequate method of contraception while on study medications and for at least 3 months following Albendazole therapy.\n* Normal laboratory values for hematocrit, platelets, white blood cells and glucose and normal or decreased values for Alanine transaminase, Aspartate transaminase and creatinine.\n* Negative PPD measurement and if positive ( \\> 9mm induration in the absence of other findings or immunosuppression ) , negative smears for TB.\n* Negative fecal exam for Taenia eggs or Strongyloides larvae.\n\nExclusion Criteria:\n\n* Primary generalized seizures ( e.g., not caused by Neurocysticercosis )\n* A history of generalized epileptic status .\n* A type of Neurocysticercosis which can expose the patient to increased risk during the study.\n* Patients with persistent or progressive symptomatic intracranial hypertension or intracranial hypertension.\n* Previous therapy with Albendazole or Praziquantel in the previous year.\n* Pulmonary tuberculosis, or symptoms compatible with tuberculosis not otherwise explained.\n* Active hepatitis\n* Systemic disease that may affect short term prognosis.\n* Patients in unstable condition ( consistently abnormal vital signs: body temperature, heart rate, respiratory rate, and blood pressure )\n* Pregnancy during antiparasitic treatment\n* History of hypersensitivity to Albendazole or Praziquantel\n* Concurrent treatment with Cimetidine or Theophylline\n* Chronic alcohol or drug abuse\n* Unwilling or unable to provide a Computed tomography initially or an Magnetic resonance imaging at 6 months ( as patients with ferromagnetic implants ) , Computed tomography at the end of therapy.\n* Unwillingness of subject or legal representative to give written informed consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PK Substudy - Area Under the Curve of Albendazole in Treatment in Day 1","description":"\\- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1412.2","spread":"58124.7"},{"groupId":"OG001","value":"1111","spread":"32257.1"}]}]}]},{"type":"PRIMARY","title":"PK Substudy - Area Under the Curve of Albendazole in Treatment Days 10 and 11","description":"\\- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4925.3","spread":null},{"groupId":"OG001","value":"2969.6","spread":null}]}]}]},{"type":"SECONDARY","title":"PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Day 1","description":"\\- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"548.3","spread":"320.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"923.7","spread":"424.7"}]}]}]},{"type":"SECONDARY","title":"PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Days 10 and 11","description":"\\- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"240.2","spread":null},{"groupId":"OG001","value":"550.1","spread":null}]}]}]},{"type":"PRIMARY","title":"PK Substudy - Maximum Concentration of Albendazole","description":"Highest serum level of Albendazole measured from all level assessments in the curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1293.9","spread":"3471.6"},{"groupId":"OG001","value":"2232.8","spread":"6500.7"}]}]}]},{"type":"SECONDARY","title":"PK Substudy - Safety of Combined Albendazole Plus Praziquantel Therapy","description":"\\- Describe if some Serious Adverse Event was associated to combined Albendazole plus Praziquantel therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase III Trial - Proportion of Cysts Which Resolved","description":"Proportion of Viable Brain Parasites which Are not Alive Anymore at 6 Months MRI","classes":[]},{"type":"PRIMARY","title":"Phase III Trial - Proportion of Patients Without Remaining Live Cysts","description":"Proportion of patients whose 6 month MR does not show viable parasites anymore","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase III Trial - Seizure Frequency","description":"Seizure frequency by treatment group","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":16},"commonTop":["Increased ALT","Increased AST","Headache","Abdominal pain","Decreased White blood cells"]}}}